Observational Study
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 7, 2021; 27(45): 7813-7830
Published online Dec 7, 2021. doi: 10.3748/wjg.v27.i45.7813
Multimodality management of gallbladder cancer can lead to a better outcome: Experience from a tertiary care oncology centre in North India
Shaifali Goel, Abhishek Aggarwal, Assif Iqbal, Vineet Talwar, Swarupa Mitra, Shivendra Singh
Shaifali Goel, Abhishek Aggarwal, Assif Iqbal, Shivendra Singh, Department of GI and HPB Oncosurgery, Rajiv Gandhi Cancer Institute and Research Center, Delhi 110085, Delhi, India
Vineet Talwar, Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Center, Delhi 110085, Delhi, India
Swarupa Mitra, Department of Radiation Oncology, Rajiv Gandhi Cancer Institute and Research Center, Delhi 110085, Delhi, India
Author contributions: Singh S was the guarantor and designed the study; Goel S, Aggarwal A, and Iqbal A participated in the acquisition, analysis, and interpretation of the data, and drafted the initial manuscript; Talwar V, Mitra S, and Singh S revised the article critically for important intellectual content.
Institutional review board statement: The local Institutional Review Board (IRB) approved the study on May 26, 2020 (No. RGCIRC/IRB-BHR/48/2020).
Informed consent statement: All patients provided informed consent prior to any intervention, chemotherapy, radiotherapy, or surgery.
Conflict-of-interest statement: There are no conflicts of interest to report.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shivendra Singh, MCh, MS, Chief and Senior consultant, Department of GI and HPB Oncosurgery, Rajiv Gandhi Cancer Institute and Research Center, Dinbandhu Choturam Marg, Sector 5, Delhi 110085, Delhi, India. shiven_24@yahoo.co.in
Received: April 26, 2021
Peer-review started: April 26, 2021
First decision: June 13, 2021
Revised: June 26, 2021
Accepted: September 2, 2021
Article in press: September 2, 2021
Published online: December 7, 2021
Processing time: 221 Days and 0 Hours
Core Tip

Core Tip: Gallbladder cancer (GBC) is an aggressive malignancy with only 10% of cases amenable to resection at presentation and a dismal overall 5-year survival rate of 5%-13% after curative surgery. Recently, several experts have recommended that multimodality treatment, including neoadjuvant and adjuvant therapies, can improve survival. In this study, we share our experience with multimodality approach in GBC. Five-year overall survival was approaching 50%, and therefore we suggest that such approach can improve survival in this aggressive malignancy.